image
Healthcare - Medical - Devices - NYSE - US
$ 149.68
5.46 %
$ 4.45 B
Market Cap
85.53
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one INSP stock under the worst case scenario is HIDDEN Compared to the current market price of 150 USD, Inspire Medical Systems, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one INSP stock under the base case scenario is HIDDEN Compared to the current market price of 150 USD, Inspire Medical Systems, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one INSP stock under the best case scenario is HIDDEN Compared to the current market price of 150 USD, Inspire Medical Systems, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart INSP

image
$220.0$220.0$210.0$210.0$200.0$200.0$190.0$190.0$180.0$180.0$170.0$170.0$160.0$160.0$150.0$150.0$140.0$140.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
803 M REVENUE
28.49%
36.1 M OPERATING INCOME
189.60%
53.5 M NET INCOME
352.96%
130 M OPERATING CASH FLOW
428.32%
-113 M INVESTING CASH FLOW
61.63%
-52.4 M FINANCING CASH FLOW
-375.58%
240 M REVENUE
17.98%
31.9 M OPERATING INCOME
122.68%
35.2 M NET INCOME
90.43%
69.2 M OPERATING CASH FLOW
32.32%
3.76 M INVESTING CASH FLOW
103.65%
-70.1 M FINANCING CASH FLOW
-709.18%
Balance Sheet Inspire Medical Systems, Inc.
image
Current Assets 631 M
Cash & Short-Term Investments 446 M
Receivables 93.1 M
Other Current Assets 92.2 M
Non-Current Assets 178 M
Long-Term Investments 71 M
PP&E 95.2 M
Other Non-Current Assets 11.3 M
55.12 %11.51 %11.40 %8.78 %11.78 %Total Assets$808.4m
Current Liabilities 88.5 M
Accounts Payable 38.7 M
Short-Term Debt 0
Other Current Liabilities 49.8 M
Non-Current Liabilities 30.2 M
Long-Term Debt 30 M
Other Non-Current Liabilities 148 K
32.60 %41.97 %25.31 %Total Liabilities$118.7m
EFFICIENCY
Earnings Waterfall Inspire Medical Systems, Inc.
image
Revenue 803 M
Cost Of Revenue 123 M
Gross Profit 680 M
Operating Expenses 644 M
Operating Income 36.1 M
Other Expenses -17.4 M
Net Income 53.5 M
900m900m800m800m700m700m600m600m500m500m400m400m300m300m200m200m100m100m00803m(123m)680m(644m)36m17m54mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
84.68% GROSS MARGIN
84.68%
4.49% OPERATING MARGIN
4.49%
6.67% NET MARGIN
6.67%
7.76% ROE
7.76%
6.62% ROA
6.62%
4.59% ROIC
4.59%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Inspire Medical Systems, Inc.
image
100m100m80m80m60m60m40m40m20m20m00(20m)(20m)(40m)(40m)(60m)(60m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 53.5 M
Depreciation & Amortization 6.55 M
Capital Expenditures -39.1 M
Stock-Based Compensation 116 M
Change in Working Capital -37.7 M
Others 2.41 M
Free Cash Flow 91.1 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Inspire Medical Systems, Inc.
image
Wall Street analysts predict an average 1-year price target for INSP of $229 , with forecasts ranging from a low of $170 to a high of $285 .
INSP Lowest Price Target Wall Street Target
170 USD 13.58%
INSP Average Price Target Wall Street Target
229 USD 53.26%
INSP Highest Price Target Wall Street Target
285 USD 90.41%
Price
Max Price Target
Min Price Target
Average Price Target
300300280280260260240240220220200200180180160160140140120120May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 11
6. Ownership
Insider Ownership Inspire Medical Systems, Inc.
image
Sold
0-3 MONTHS
5.95 M USD 2
3-6 MONTHS
1.7 M USD 1
6-9 MONTHS
5.16 M USD 3
9-12 MONTHS
3.45 M USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Inspire Medical Systems, Inc. to Report First Quarter 2025 Financial Results on May 5, 2025 MINNEAPOLIS, April 01, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the first quarter 2025 after the close of trading on Monday, May 5. Inspire's management team will host a corresponding conference call beginning at 5:00 p.m. globenewswire.com - 1 week ago
Inspire Medical Systems, Inc. to Present at the KeyBanc Capital Markets Healthcare Forum MINNEAPOLIS, March 06, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the KeyBanc Capital Markets Healthcare Forum on Tuesday, March 18, 2025. globenewswire.com - 1 month ago
Here's Why Inspire Medical Systems (INSP) is a Strong Momentum Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. zacks.com - 1 month ago
SHAREHOLDER ALERT: Kaskela Law LLC Announces Shareholder Investigation of Inspire Medical Systems, Inc. (NYSE: INSP) and Encourages Long-Term Inspire Investors to Contact the Firm PHILADELPHIA, Feb. 17, 2025 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire Medical”) on behalf of the company's long-term shareholders. globenewswire.com - 1 month ago
How Much Upside is Left in Inspire (INSP)? Wall Street Analysts Think 25.88% The consensus price target hints at a 25.9% upside potential for Inspire (INSP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. zacks.com - 1 month ago
INSP Stock Declines Despite Q4 Earnings Beat, Gross Margin Contracts Inspire Medical's both geographic segments witness strong revenue growth on the back of solid product demand in the fourth quarter. zacks.com - 1 month ago
Inspire Medical Systems, Inc. (INSP) Q4 2024 Earnings Call Transcript Inspire Medical Systems, Inc. (NYSE:INSP ) Q4 2024 Earnings Conference Call February 10, 2025 5:00 PM ET Company Participants Ezgi Yagci - Vice President of Investor Relations Tim Herbert - President & Chief Executive Officer Rick Buchholz - Chief Financial Officer Conference Call Participants Travis Steed - Bank of America Securities Danielle Antalffy - UBS Robbie Marcus - JPMorgan Chris Pasquale - Nephron Research Anthony Petrone - Mizuho Financial Group Richard Newitter - Truist Securities David Rescott - Baird Adam Maeder - Piper Sandler Larry Biegelsen - Wells Fargo Shagun Singh - RBC Capital Markets Brett Fishbin - KeyBanc Capital Markets Jon Block - Stifel Michael Polark - Wolfe Research Mike Kratky - Leerink Partners Suraj Kalia - Oppenheimer & Co. Operator Good afternoon. My name is Dilem [ph] and I'll be your conference operator today. seekingalpha.com - 1 month ago
Inspire Medical's Earnings Surge in Q4 Inspire Medical Systems (INSP -0.64%), known for its innovative devices that use neurostimulation to treat sleep apnea, announced impressive fourth-quarter results on Feb. 10. Earnings per share (EPS) came in at $1.15, well ahead of the $0.73 consensus estimate. fool.com - 1 month ago
Inspire (INSP) Reports Q4 Earnings: What Key Metrics Have to Say Although the revenue and EPS for Inspire (INSP) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. zacks.com - 1 month ago
Inspire Medical Systems (INSP) Q4 Earnings and Revenues Surpass Estimates Inspire Medical Systems (INSP) came out with quarterly earnings of $1.15 per share, beating the Zacks Consensus Estimate of $0.74 per share. This compares to earnings of $0.49 per share a year ago. zacks.com - 1 month ago
Inspire Medical Systems, Inc. Announces Fourth Quarter and Full Year 2024 Financial Results and Updates 2025 Outlook Inspire Reports Year-over-Year Revenue Growth of 25% and Earnings per Share Growth of 135% for the Fourth Quarter 2024 Inspire Reports Year-over-Year Revenue Growth of 25% and Earnings per Share Growth of 135% for the Fourth Quarter 2024 globenewswire.com - 1 month ago
Countdown to Inspire (INSP) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS Beyond analysts' top -and-bottom-line estimates for Inspire (INSP), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024. zacks.com - 2 months ago
8. Profile Summary

Inspire Medical Systems, Inc. INSP

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 4.45 B
Dividend Yield 0.00%
Description Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, a closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.
Contact 5500 Wayzata Boulevard, Golden Valley, MN, 55416 https://www.inspiresleep.com
IPO Date May 3, 2018
Employees 1246
Officers Mr. Timothy P. Herbert Founder, Chairman, Chief Executive Officer & President Mr. Richard J. Buchholz Chief Financial Officer Mr. Randall A. Ban EVice President of Patient Access &Therapy Development Mr. Andreas Henke Executive Vice President & MD of Europe Mr. Bryan K. Phillips J.D. Senior Vice President, General Counsel, Chief Compliance Officer & Corporate Secretary Mr. Carlton W. Weatherby Chief Strategy and Growth Officer Mr. Ivan Lubogo SVice President of Strategic Sales Ms. Ezgi Yagci Vice President of Investor Relations Mr. John C. Rondoni Chief Technology Officer Ms. Melissa J. Mann Chief People Officer